ImageneBio News and Activities

ImageneBio is a company listed under the stock ticker IMA (US).

Acquisition, funding and merger involving ImageneBio.

• ImageneBio is now listed under ticker IMA. (posted on July 25 2025).
• Ikena Oncology will change its company name to ImageneBio. (posted on July 24 2025).
• Inmagene Biopharmaceuticals and ImageneBio have merged  (posted on July 24 2025)..

View the org chart displaying its 20 main executives

Most searched biographies at ImageneBio

• Kristin Yarema, Chief Executive Officer and Interim Chief Financia...
• Joseph Slattery, Director
• David Bonita, Director

Popular executive movements at ImageneBio

• Matt Robbins has joined the company as General Counsel  (posted on July 8 2026).
• Robert Lally, Senior Vice President of Finance and Operations, will leave the company on Jul. 22, 2026  (posted on June 29 2026).
• Benjamin Porter-Brown will join the company as Chief Medical Officer on Feb. 16, 2026  (posted on February 12 2026).

Click here to view some more movements at ImageneBio

Create your alert
to follow the executive moves at ImageneBio.

ImageneBio has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• The new name of ChemoTech is Neem’s Hill. (posted on July 15 2026).
• Archimed Group has acquired Esperion Therapeutics (posted on July 14 2026).
• MindRank has just announced a $52 Million fundraising (posted on July 14 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by ImageneBio

• ImageneBio Appoints Matt Robbins as General Counsel | ImageneBio, Inc.
• Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022 | Ikena Oncology
• Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma | Ikena Oncology
• Ikena Oncology to Participate in Spring 2022 Investor Conferences | Ikena Oncology
• Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update | Ikena Oncology
• Ikena Oncology and Vall d’Hebron Institute of Oncology Announce Research & Development Collaboration | Ikena Oncology
• Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting | Ikena Oncology
• Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting | Ikena Oncology
• Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update | Ikena Oncology
• Ikena Appoints Richard Wooster, Ph.D., to its Board of Directors | Ikena Oncology
• View more press releases Close

Social media about ImageneBio

• ImageneBio on Wikipedia, Google News & Yahoo Finance
• ImageneBio on LinkedIn, X (Twitter) & YouTube